Zomedica Corp (ZOM) stock is rebounding to $1.36 per share, up by 1.88% as of 11:25 a.m. today. Notable, the company has not released any positive news recently.

In fact, the stock continues to fall since the company said that the first commercial sale of its Truforma platform. However, those investors who own this stock still believe that the company can achieve profit growth by selling Truforma.

In addition, the company said that the global veterinary immunodiagnostic market has been predicted to expand at a CAGR of 9.6% and reach $2.1 billion by the year 2022. It seems that the prospects for Truforma are bright.

However, this ​is difficult to maintain a market value of $1.29 billion for a company without being profitable. Some investors looking to lower the price of this stock and realize the purpose of price correction. Anyway, investors should see the sales data of its Truforma platform in the next financial results and make better decisions at that time.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.